Who are Carperitide heart failure therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natrecor, nesiritide, furosemide, Nesiritide (Natrecor), recombinant human BNP(1-32), rhBNP, recombinant B-type, natriuretic peptide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carperitide-heart-failure-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Carperitide heart failure therapy — Competitive Intelligence Brief

Carperitide heart failure therapy (Carperitide heart failure therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Natriuretic peptide. Area: Cardiovascular.

marketed Natriuretic peptide Natriuretic peptide receptor-A (NPR-A) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Carperitide heart failure therapy (Carperitide heart failure therapy) — Nara Medical University. Carperitide is a recombinant human atrial natriuretic peptide (ANP) that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and improve cardiac output in heart failure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carperitide heart failure therapy TARGET	Carperitide heart failure therapy	Nara Medical University	marketed	Natriuretic peptide	Natriuretic peptide receptor-A (NPR-A)
Natrecor	NESIRITIDE	Scios Llc	marketed	Natriuretic Peptide	Atrial natriuretic peptide receptor 1	2001-01-01
nesiritide, furosemide	nesiritide, furosemide	Scios, Inc.	marketed	Natriuretic peptide analog and loop diuretic combination	Natriuretic peptide receptor-A (NPR-A) and Na-K-2Cl cotransporter
Nesiritide (Natrecor)	Nesiritide (Natrecor)	M.D. Anderson Cancer Center	marketed	Natriuretic peptide	Natriuretic peptide receptor-A (NPR-A)
recombinant human BNP(1-32)	recombinant human BNP(1-32)	VA Office of Research and Development	marketed	Natriuretic peptide	Natriuretic peptide receptor-A (NPR-A)
rhBNP	rhBNP	LI ZHAO	marketed	Natriuretic peptide	Natriuretic peptide receptor-A (NPR-A)
recombinant B-type, natriuretic peptide	recombinant B-type, natriuretic peptide	University of Texas Southwestern Medical Center	marketed	Natriuretic peptides	Natriuretic peptide receptor-A (NPR-A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Natriuretic peptide class)

LI ZHAO · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Nara Medical University · 1 drug in this class
Scios, Inc. · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carperitide heart failure therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/carperitide-heart-failure-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab